BridgeBio Pharma, Inc. finds, develops, and delivers various medicines for genetic diseases. The company has a pipeline of 15 development
programs that include product candidates ranging from early discovery to late-stage development in various therapeutic areas, including genetic dermatology, oncology, cardiology, neurology, endocrinology, renal disease, and ophthalmology. Its principal products in development programs include BBP-265, an oral small molecule transthyretin (TTR) for the treatment of TTR amyloidosis, including cardiomyopathy and polyneuropathy manifestations; infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor for the treatment of FGFR-driven cancers, as well as for the treatment of achondroplasia; BBP-631, a preclinical adeno-associated virus gene transfer product candidate for the treatment of congenital adrenal hyperplasia caused by 21OHD; and BBP-454, a preclinical development program for small molecule inhibitors of KRAS for the treatment of pan-mutant KRAS-driven cancers. The company also engages in developing BBP-418, a substrate supplementation therapy for the treatment of limb-girdle muscular dystrophy type 2i. BridgeBio Pharma, Inc. was founded in 2015 and is headquartered in Palo Alto, California. The company trades on NASDAQ exchange. The company headquarter is located in Palo Alto, CA. The company was established in the 2015.
| Ticker | BBIO |
| Long Name | Bridgebio Pharma, Inc. |
| Short Name | Bridgebio Pharma |